Abeona Therapeutics Inc. (ABEO): who owns it and who trades it
As of Nov 16, 2026, ABEO insiders reported 37 open-market sales worth $3.5M and 1 purchase worth $34.3K in the last 12 months, with 19% of the sale value made under pre-set 10b5-1 plans. The largest seller was Vishwas Seshadri (CEO), with $1.5M. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Abeona Therapeutics
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ABEO
127 funds and institutions reported ABEO shares worth $276M at the end of Q2 2026, about 78% of the company. The largest holder is Nantahala Capital Management, LLC with 18.0%.
Funds and institutions (13F) 78%Everyone else 22%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 10.27M | 18.01% | $63.5M | +105% |
| BlackRock, Inc. | 3.35M | 5.88% | $20.7M | +5% |
| Cable Car Capital, LP | 3.01M | 5.27% | $18.6M | No change |
| AIGH Capital Management LLC | 2.99M | 5.24% | $18.5M | -4% |
| Vanguard Capital Management LLC | 2.21M | 3.88% | $13.7M | +2% |
| OneDigital Investment Advisors LLC | 1.65M | 2.90% | $10.2M | – |
| AWM Investment Company, Inc. | 1.49M | 2.61% | $9.2M | +85% |
| Geode Capital Management, LLC | 1.26M | 2.21% | $7.8M | +4% |
| Kennedy Capital Management LLC | 1.24M | 2.17% | $7.7M | -2% |
| Goldman Sachs Group Inc | 1.22M | 2.15% | $7.6M | +8% |
| State Street Corp | 1.04M | 1.82% | $6.4M | +9% |
| Propel Bio Management, LLC | 983,070 | 1.72% | $6.1M | -26% |
| Nan Fung Trinity (hk) Ltd | 956,770 | 1.68% | $5.9M | No change |
| Diametric Capital, LP | 755,021 | 1.32% | $4.7M | +23% |
| J. Goldman & Co LP | 678,173 | 1.19% | $4.2M | +6% |
| Silverarc Capital Management, LLC | 610,407 | 1.07% | $3.8M | -6% |
| Rubric Capital Management LP | 608,771 | 1.07% | $3.8M | – |
| Stonepine Capital Management, LLC | 557,284 | 0.98% | $3.4M | -25% |
| Northern Trust Corp | 552,630 | 0.97% | $3.4M | +27% |
| Citigroup Inc | 548,300 | 0.96% | $3.4M | +5% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ABEO insiders reported $34.3K of open-market purchases and $3.5M of sales. 19% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Faith L. Charles | Director | Purchase | 15,000 | $2.29 | $34.3K | Form 4 |
| Sep 29, 2026 | Vishwas Seshadri | CEO | Sale | 19,608 | $5.16 | $101K | Form 4 |
| Sep 29, 2026 | Joseph Walter Vazzano | CFO | Sale | 9,191 | $5.16 | $47.4K | Form 4 |
| Sep 29, 2026 | Brendan M. O'Malley | Vice president | Sale | 6,727 | $5.16 | $34.7K | Form 4 |
| Sep 29, 2026 | Madhav Vasanthavada | Chief Commercial Officer | Sale | 4,902 | $5.16 | $25.3K | Form 4 |
| Sep 1, 2026 | Mark Alvino | Director | Sale | 15,000 | $5.86 | $87.9K | Form 4 |
| Jul 21, 2026 | Joseph Walter Vazzano | CFO | Sale | 1,478 | $6.53 | $9.7K | Form 4 |
| Jul 9, 2026 | Joseph Walter Vazzano | CFO | Sale | 24,880 | $6.96 | $173K | Form 4 |
| Jul 9, 2026 | Vishwas Seshadri | CEO | Sale | 67,971 | $6.96 | $473K | Form 4 |
| Jul 9, 2026 | Brendan M. O'Malley | Vice president | Sale | 12,050 | $6.96 | $83.9K | Form 4 |
| Jul 9, 2026 | Madhav Vasanthavada | Chief Commercial Officer | Sale | 12,606 | $6.96 | $87.7K | Form 4 |
| Jun 30, 2026 | Leila Alland | Director | Sale | 11,000 | $5.92 | $65.1K | Form 4 |
| Jun 15, 2026 | Christine Berni Silverstein | Director | Sale | 18,160 | $5.71 | $104K | Form 4 |
| Jun 9, 2026 | Joseph Walter Vazzano | CFO | Sale plan | 13,421 | $5.30 | $71.1K | Form 4 |
| Jun 9, 2026 | Brendan M. O'Malley | Vice president | Sale | 6,305 | $5.30 | $33.4K | Form 4 |
| Jun 9, 2026 | Joseph Walter Vazzano | CFO | Sale plan | 25,646 | $5.39 | $138K | Form 4 |
| Jun 9, 2026 | Vishwas Seshadri | CEO | Sale | 31,916 | $5.30 | $169K | Form 4 |
| Jun 9, 2026 | Madhav Vasanthavada | Chief Commercial Officer | Sale | 5,450 | $5.30 | $28.9K | Form 4 |
| Jun 8, 2026 | Vishwas Seshadri | CEO | Sale | 24,428 | $5.43 | $133K | Form 4 |
| Jun 8, 2026 | Joseph Walter Vazzano | CFO | Sale plan | 10,271 | $5.43 | $55.8K | Form 4 |
| Jun 8, 2026 | Brendan M. O'Malley | Vice president | Sale | 4,826 | $5.43 | $26.2K | Form 4 |
| Jun 8, 2026 | Madhav Vasanthavada | Chief Commercial Officer | Sale | 4,170 | $5.43 | $22.6K | Form 4 |
| May 22, 2026 | Mark Alvino | Director | Sale | 6,500 | $5.46 | $35.5K | Form 4 |
| May 15, 2026 | Eric Crombez | Director | Sale plan | 26,143 | $5.53 | $145K | Form 4 |
| May 11, 2026 | Madhav Vasanthavada | Chief Commercial Officer | Sale | 5,548 | $5.96 | $33.1K | Form 4 |
| Mar 31, 2026 | Vishwas Seshadri | CEO | Sale plan | 29,985 | $4.38 | $131K | Form 4 |
| Mar 16, 2026 | Joseph Walter Vazzano | CFO | Sale | 785 | $4.76 | $3.7K | Form 4 |
| Feb 2, 2026 | Christine Berni Silverstein | Director | Sale | 20,070 | $5.09 | $102K | Form 4 |
| Feb 2, 2026 | Donald A. Wuchterl | Director | Sale | 14,814 | $5.09 | $75.4K | Form 4 |
| Feb 2, 2026 | Eric Crombez | Director | Sale | 16,284 | $5.09 | $82.9K | Form 4 |
| Feb 2, 2026 | Leila Alland | Director | Sale | 18,065 | $5.09 | $92K | Form 4 |
| Feb 2, 2026 | Mark Alvino | Director | Sale | 2,000 | $5.09 | $10.2K | Form 4 |
| Jan 22, 2026 | Madhav Vasanthavada | Chief Commercial Officer | Sale | 12,610 | $5.29 | $66.7K | Form 4 |
| Jan 22, 2026 | Joseph Walter Vazzano | CFO | Sale | 18,666 | $5.33 | $99.5K | Form 4 |
| Jan 22, 2026 | Vishwas Seshadri | CEO | Sale | 69,832 | $5.33 | $372K | Form 4 |
| Jan 22, 2026 | Brendan M. O'Malley | Vice president | Sale | 13,578 | $5.33 | $72.4K | Form 4 |
| Jan 21, 2026 | Mark Alvino | Director | Sale | 13,500 | $5.23 | $70.6K | Form 4 |
| Dec 29, 2025 | Vishwas Seshadri | CEO | Sale plan | 25,000 | $5.31 | $133K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Vishwas Seshadri | Chief Executive Officer, Director | – | $1.5M | Sep 29, 2026 |
| Joseph Walter Vazzano | Chief Financial Officer | – | $599K | Sep 29, 2026 |
| Madhav Vasanthavada | Chief Commercial Officer | – | $264K | Sep 29, 2026 |
| Brendan M. O'Malley | SVP, Chief Legal Officer | – | $251K | Sep 29, 2026 |
| Eric Crombez | Director | – | $227K | May 15, 2026 |
| Christine Berni Silverstein | Director | – | $206K | Jun 15, 2026 |
| Mark Alvino | Director | – | $204K | Sep 1, 2026 |
| Leila Alland | Director | – | $157K | Jun 30, 2026 |
| Donald A. Wuchterl | Director | – | $75.4K | Feb 2, 2026 |
| Faith L. Charles | Director | $34.3K | – | Nov 13, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ABEO short interest
Very high short interest. 29.5% of ABEO shares are sold short: about 1 share in 3. Over the last 12 reports the number of shares short went up 17%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 16.88M ABEO shares were sold short, 29.5% of the shares outstanding, down 1.9% from the report before. At the average daily volume of 778,947 shares, buying them all back would take about 21.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 16.88M | 29.52% | -2% | 778,947 | 21.7 |
| Oct 15, 2026 | 17.21M | 30.10% | +2% | 1.36M | 12.7 |
| Sep 30, 2026 | 16.88M | 29.52% | +7% | 1.46M | 11.6 |
| Sep 15, 2026 | 15.75M | 27.53% | +4% | 1.31M | 12.0 |
| Aug 31, 2026 | 15.16M | 26.51% | +6% | 1.09M | 13.9 |
| Aug 14, 2026 | 14.27M | 24.96% | +5% | 2.08M | 6.9 |
| Jul 31, 2026 | 13.64M | 23.91% | +3% | 1.06M | 12.9 |
| Jul 15, 2026 | 13.23M | 23.20% | -3% | 1.60M | 8.3 |
| Jun 30, 2026 | 13.68M | 23.98% | -3% | 1.58M | 8.7 |
| Jun 15, 2026 | 14.14M | 24.78% | -2% | 860,472 | 16.4 |
| May 29, 2026 | 14.39M | 25.23% | -1% | 877,332 | 16.4 |
| May 15, 2026 | 14.47M | 25.36% | -12% | 1.42M | 10.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Abeona Therapeutics company events
Abeona Therapeutics filed 13 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Nov 9, 2026DealThe information contained above in Item 1.01 is hereby incorporated by reference into this Item 2.01. Filing
- Sep 15, 2026AnnouncementShared information with investors. Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Jun 12, 2026VoteReported shareholder vote results. Filing
- Jun 12, 2026LeadershipMichael Amoroso resigned as a member of the Board of Directors of Abeona Therapeutics Inc. effective immediately. Filing
- Jun 10, 2026AnnouncementShared information with investors. Filing
- Jun 4, 2026AnnouncementAbeona Therapeutics Inc. participated in a pre-Investigational New Drug application meeting with the U.S. Food and Drug Administration regarding ABO-701, a recently licensed radically novel engineered T-cell therapy, targeting Prostate-Specific Membrane Antigen to treat prostate cancer. Filing
- May 13, 2026ResultsReleased financial results. Filing
- Apr 7, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Filing
- Mar 20, 2026RulesChanged its bylaws or articles. Filing
- Mar 17, 2026ResultsReleased financial results. Filing
- Mar 9, 2026AnnouncementAbeona Therapeutics Inc. issued a press release entitled “Abeona Therapeutics ® Provides Business Update Highlighting Building Momentum in ZEVASKYN ® Commercial Launch.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Abeona Therapeutics financials
Famous investors that hold ABEO
2 of the 50 well-known investors we track reported holding ABEO in their latest 13F filing. The largest position is Israel Englander's, worth $860K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 163,890 | $860K | 0.0% | -22% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 16,898 | $88.7K | 0.0% | -93% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 10 filings named ABEO in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Rubric Capital Management LP | 13G | 5.8% |
| Nov 16, 2026 | TPG GP A, LLC | 13G | 7.0% |
| Nov 16, 2026 | Rubric Capital Management LP | 13G | 5.8% |
| Nov 16, 2026 | TPG GP A, LLC | 13G | 7.0% |
| Nov 13, 2026 | Funicular Funds, LP | 13G/A | 7.5% |
| Nov 13, 2026 | Funicular Funds, LP | 13G/A | 7.5% |
| Nov 12, 2026 | Daniel Kaufman | 13G/A | 7.3% |
| Nov 12, 2026 | Daniel Kaufman | 13G/A | 7.3% |
| Oct 23, 2026 | James Russell Revocable Trust | 13D | 6.1% |
| Oct 23, 2026 | James Russell Revocable Trust | 13D | 6.1% |
Questions about Abeona Therapeutics Inc. (ABEO) stock
Who owns the most ABEO stock?
The largest reported owner of Abeona Therapeutics Inc. (ABEO) is Nantahala Capital Management, LLC, with 18.0% of the company. In total, 127 funds and institutions reported holding ABEO at the end of Q2 2026, together about 78% of the shares. See the largest owners.
Are ABEO insiders buying or selling?
In the last 12 months, ABEO insiders reported 1 open-market purchase worth $34.3K and 37 sales worth $3.5M. The latest trade was on Nov 13, 2026. See every trade.
What is the short interest in ABEO?
As of Oct 30, 2026, 16.88M ABEO shares were sold short, 29.5% of the shares outstanding, down 1.9% from the report before. At the average daily volume of 778,947 shares, buying them all back would take about 21.7 trading days (days to cover). See the history.
Which famous investors hold ABEO?
2 of the 50 well-known investors we track reported ABEO in their latest 13F filing, including Israel Englander, Ken Griffin. The largest position is worth $860K. See all holders.
Executive pay
Abeona Therapeutics's chief executive was paid a total of $4M for the year ended Dec 31, 2025, up 14% from $3.5M the year before. In the last 12 months, Abeona Therapeutics's executives and directors bought $34.3K of stock on the open market and sold $3.5M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.